Recently, a new indication for the Novo Nordisk weight loss therapy Wegovy (Smegglutide) injection has been approved by the US FDA to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight, but should be used in combination with a low calorie diet and increased exercise activity. As a result, Smegglutide became the first weight loss drug approved to assist adults with cardiovascular disease, obesity, or overweight in preventing major cardiovascular events. (He Xinyi)